Your Patient Can't Find Their Seizure Medication — Now What?

You've prescribed Briviact (brivaracetam) because it's the right medication for your patient's seizure control. But now they're calling your office because their pharmacy doesn't carry it, can't order it, or says it's on backorder. This scenario is frustratingly common with specialty antiepileptics, and Briviact is one of the more frequent offenders.

This guide is for neurologists, epileptologists, and primary care physicians who want practical steps to help patients access their prescribed Briviact — not a clinical review, but a logistics playbook.

Current Availability Picture

As of early 2026, Briviact is not in a formal drug shortage. UCB manufactures all formulations (tablets, oral solution, and IV injection) without reported supply interruptions. The problem isn't manufacturing — it's distribution and pharmacy stocking.

Key facts:

• Most chain pharmacies (CVS, Walgreens, Rite Aid) do not routinely stock Briviact unless they have regular patients filling it
• Briviact is a DEA Schedule V controlled substance, adding inventory management overhead for pharmacies
• Generic brivaracetam oral solution was approved in February 2026 (Lupin), but generic tablets aren't widely distributed yet
• The medication scores approximately 55/100 on findability — harder to locate than most common prescriptions but not impossible

Why Your Patients Can't Find It

Understanding the bottlenecks helps you advise patients more effectively:

1. Low Prescription Volume = Low Stocking Priority

Pharmacy inventory systems are demand-driven. If a location fills fewer than 2-3 Briviact prescriptions per month, automated reordering won't trigger. The medication literally doesn't make it onto the shelf.

2. Wholesaler Access Varies

Not every pharmacy uses the same drug wholesaler, and not every wholesaler agreement includes the full UCB product line. A pharmacy that wants to order Briviact may not be able to through their primary supplier.

3. Controlled Substance Friction

Even at Schedule V, controlled substances require separate ordering, logging, and storage protocols. For a medication with minimal local demand, some pharmacy managers decide the administrative overhead isn't worth it.

4. Insurance Hurdles Compound the Problem

Patients who finally locate a pharmacy with stock may then face prior authorization denials or high copays — adding another round of delays on top of the supply challenge.

What Providers Can Do: 5 Practical Steps

Step 1: Build a Reliable Pharmacy List

Invest 15 minutes to identify 2-3 pharmacies in your area that reliably stock Briviact. Good candidates include:

• Independent pharmacies near your practice — they're often willing to stock medications their local providers frequently prescribe
• Specialty pharmacies that focus on neurology or complex medications
• Hospital outpatient pharmacies — they often carry a broader formulary

Use Medfinder for Providers to check real-time availability. Once you've identified reliable sources, keep the list in your EHR or share it with your clinical team.

Step 2: Send Prescriptions to the Right Place

Don't default to "send to CVS on Main Street" if you know they won't have it. When you identify that a patient needs Briviact, proactively route the prescription to a pharmacy you know stocks it. This saves the patient days of phone calls and prevents dangerous gaps in therapy.

Step 3: Provide Prior Authorization Support Upfront

Most commercial insurers and Medicare Part D plans require prior authorization for Briviact, often with step therapy through levetiracetam first. Prepare for this:

• Document levetiracetam trial and reason for discontinuation (most commonly: irritability, aggression, mood changes, or inadequate seizure control)
• Submit PA paperwork at the time of prescribing, not after the patient gets to the pharmacy and gets rejected
• Keep a template PA letter for Briviact in your practice — it speeds up the process significantly

Step 4: Write 90-Day Prescriptions When Possible

Longer prescription durations reduce the frequency of fill attempts, giving patients more buffer if a pharmacy needs a few days to order the medication. Check your state's controlled substance prescribing regulations for Schedule V limitations.

Step 5: Educate Patients on Self-Advocacy Tools

Empower your patients with practical resources:

• Direct them to Medfinder to find pharmacies with Briviact in stock
• Provide information about the UCB Savings Card (commercially insured patients may pay as little as $10/rx)
• Share the UCB Patient Assistance Program details for uninsured patients
• Recommend they start refill processes 7-10 days early to account for ordering delays

When to Consider Alternatives

If a patient faces chronic access problems with Briviact, a therapeutic discussion may be warranted. Keep in mind:

• Levetiracetam (Keppra): Widely available, very affordable ($15-50/month generic), but many Briviact patients were specifically switched away from levetiracetam due to behavioral side effects
• Lacosamide (Vimpat): Different mechanism, generally well-tolerated, generic available — but also Schedule V and not universally stocked
• Cenobamate (Xcopri): Newer option for focal seizures, brand-only at $800-1,200/month
• Perampanel (Fycompa): AMPA receptor antagonist, brand-only, Schedule III

For a patient-facing comparison of alternatives, you can share: Alternatives to Briviact.

Workflow Tips for Your Practice

• Flag Briviact patients in your EHR. When they call about fill problems, your staff knows to check specialty pharmacy options immediately rather than troubleshooting from scratch.
• Coordinate with your medical assistant or pharmacy liaison. A quick call from your office to a pharmacy can often resolve stock issues faster than the patient calling independently.
• Track patterns. If multiple patients report access issues from the same area, it may be worth reaching out to a local independent pharmacy about establishing a regular Briviact supply.

Final Thoughts

Briviact access problems are a logistics issue, not a clinical one. The medication works well for many patients with focal seizures, and the arrival of generic competition should gradually improve the situation. In the meantime, proactive prescribing — routing to reliable pharmacies, handling PA upfront, and equipping patients with self-advocacy tools — can prevent most fill failures.

For related provider resources, see: Briviact Shortage: What Providers Need to Know and How to Help Patients Save Money on Briviact.